In this study, we found that mutations in CCT5 are most common in LUSC (> 10%), followed by Esophageal Adenocarcinoma (EAC), Bladder Urothelial Carcinoma (BLCA), and Lung Adenocarcinoma (LUAD), which cumulatively indicates that CCT5 mutations influence cancer progression in different tissues. Here, CCT5 is linked to cancer.